Statera Biopharma, Inc. — Cyborg Score 4/10

Strategic Profile

Through its Advanced Immunomodulating Multi-Component System (AIMS) platform, the company has advanced several late-stage developmental product candidates. The company has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis.

Cyborg Score Rationale

Statera is a clinical-stage biotech with a validated merger (2021) combining experienced management from Cleveland BioLabs. The company has multiple programs in development and raised $2.0 million in February 2022, but the stock migrated from NASDAQ to OTC in recent years, reflecting market capitalization decline and typical early-stage biotech cash constraints.

Top Insights

• Proprietary AIMS platform enables multi-component immunotherapy combinations for immune restoration
• Pipeline spans multiple therapeutic areas: autoimmune (Crohn's), oncology (pancreatic cancer), hematology, infectious disease, and CNS
• Formed through strategic 2021 merger combining Cleveland BioLabs' immunotherapy expertise with Cytocom's platform
• Currently trading OTC after NASDAQ delisting, signaling earlier-stage capital constraints typical of clinical-stage biotech

Named Competitors

• Moderna — mRNA-based immunotherapeutics and vaccines
• Adaptimmune — Cell therapy and engineered T-cell immunotherapies
• Syndax Pharmaceuticals — Immuno-oncology and immune-modulation therapeutics

Recent Developments

• (March 2023) Entered broad licensing agreement to expand pipeline and partnership network
• (February 2022) Priced $2.0 million registered direct offering of common stock and warrants to fund operations

Open the full interactive Statera Biopharma, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.